ABSTRACT:
Nitrosamine impurities are a group of chemical compounds that have raised concerns due to their potential carcinogenicity. Nitrosamines are taken orally by humans from food and medicine. N-nitroso compounds (NOC) are exposed by human beings from food, tobacco smoking, medicines and other environmental sources. The recent discovery of nitrosamines made huge changes in the pharmaceutical world. Safety issues has been found in few drugs like valsartan, tetrazole-containing angiotensin-II receptor blockers, ranitidine, and metformin etc... due to the unacceptable levels of N-nitroso compounds. These nitrosamine impurities may form if an amine compound reacts with a nitrosating agent under suitable conditions (viz., temperature, pH etc.) during the manufacturing and storage of the product. To ensure the quality and safety of the drug product, drug regulatory agencies throughout the world have introduced stringent measures on nitrosamine contamination for all drug products in the market. To comply current regulatory requirements, many drug products have been recalled and it causes shortage of medicines in the market. Hence, omission or prevention of nitrosamine impurities in drug products is essential to meet daily medicine needs for human beings and to enhance human lifespan. In this review on Nitrosamine discussed the classifications, Toxicity, acceptable intakes, limit calculations and control measures gives you a significant knowledge and awareness on Nitrosamine.
Cite this article:
Baratam Kasinath, Boddu Veeraswami. Research Journal of Pharmacy and Technology. 2025;18(10):5041-6. doi: 10.52711/0974-360X.2025.00728
Cite(Electronic):
Baratam Kasinath, Boddu Veeraswami. Research Journal of Pharmacy and Technology. 2025;18(10):5041-6. doi: 10.52711/0974-360X.2025.00728 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-10-67
REFERENCES:
1. Control of Nitrosamine Impurities in Human Drugs. U.S. Food and Drug Administration, USA. https://www.fda.gov/media/141720
2. Loeppky RN. Nitrosamine and N-Nitroso Compound Chemistry and Biochemistry Advances and Perspectives. ACS Symposium series. American Chemical Society. 1994; 553: 1-18. doi: 10.1021/bk-1994-0553.ch001
3. Hiroshi YH et al., Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis. 1992; 13(10): 1789 - 1794. doi: 10.1093/carcin/13.10.1789.
4. Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms ad carcinogenic potential. Mutation Research. 1991; 259(3–4): 277–89. doi: 10.1016/0165-1218(91)90123-4.
5. Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products. U.S. Food and Drug Administration, USA. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/prinston-pharmaceutical-inc-issues-voluntary-nationwide-recall-valsartan-and-valsartan-hctz-tablets
6. Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API). U.S. Food and Drug Administration, USA. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sciegen-pharmaceuticals-inc-issues-voluntary-nationwide-recall-irbesartan-tablets-usp-75-mg-150-mg
7. Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API). U.S. Food and Drug Administration, USA. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-losartan-potassium-and-hydrochlorothiazide-due
8. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan). U.S. Food and Drug Administration, USA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
9. Nitrosamines: EMA aligns recommendations for sartans with those for other medicines. EMA/134937/2021. https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns_en-0.pdf
10. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. U.S. Food and Drug Administration, USA. https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine
11. Statement from Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S. U.S. Food and Drug Administration, USA. https://www.fda.gov/news-events/press-announcements/statement-janet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found
12. Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Nizatidine Oral Solution, 15 mg/mL, Due to Potential Levels of N-nitrosodimethylamine (NDMA) Impurity Amounts Above the Levels Established by FDA. U.S. Food and Drug Administration, USA. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-nizatidine-oral-solution-15-mgml-due
13. IARC Monographs on the Identification of Carcinogenic Hazards to Humans. World Health Organization. https://monographs.iarc.fr/list-of-classifications
14. Karishma PF and Vinod HJ. Insight into Analytical Techniques for the Detection of Nitrosamine Impurities: A Review. Asian Journal of Pharmaceutical Analysis. 2023; 13(1): 30-4. doi: 10.52711/2231-5675.2023.00005
15. Ajay IP et al. Nitrosamine Impurity: Management of Unwelcome Guest in Pharma Market. Asian Journal of Pharmaceutical Analysis. 2023; 13(4): 303-8. doi: 10.52711/2231-5675.2023.00049
16. Ashok BP et al. A Brief Review on Genotoxic impurities in Pharmaceuticals. Asian Journal of Pharmaceutical Research. 2021; 11(3): 187-3. doi: 10.52711/2231-5691.2021.00034
17. Ahamed Noor M et al. A Review on Genotoxicity. Asian Journal of Pharmaceutical Research. July-Sept. 2014; 4(3): 162-165.
18. Samrat Debnath et al. Impurity Linked Genotoxicity assessment of the Antineoplastic Chemotherapy agent using Ames model. Research Journal of Pharmacy and Technology. 2023; 16(7): 3339-2. doi: 10.52711/0974-360X.2023.00551
19. Hassan Jaddi et al. Synthesis and genotoxic evaluation of a 4-(Oxiran-2-ylmethyl)-1,4-benzothiazin-3-one. Research Journal of Pharmacy and Technology. 2022; 15(11): 5217-4. doi: 10.52711/0974-360X.2022.00879
20. Meera Sumanth et al. Genotoxicity Testing of Lipovedic- A Polyherbal Anti-hypercholesterolemic Drug. Research Journal of Pharmacy and Technology. Aug. 20114, (8): Page 1189-1192
21. Anil Kumar K et al. Determination of Genotoxic Impurities in Nilotinib using LC-MS Method. Research Journal of Pharmacy and Technology. 2024; 17(3): 1003-7. doi: 10.52711/0974-360X.2024.00155
22. Moushumi BJ et al. In Vivo Evaluation of Genotoxic Effects of Sivanar Amirtham Formulation on Rats Using Micro Nucleus Assay. Research Journal of Pharmacy and Technology. 2022; 15(11): 5017-0. doi: 10.52711/0974-360X.2022.00843
23. Alexander ML al. Evaluation of genotoxicity in buccal mucosa of patients subjected to X-rays by degenerative nuclear alterations study. Research Journal of Pharmacy and Technology. 2021; 14(11):5845-8. Doi: doi: 10.52711/0974-360X.2021.01017
24. Veeraswami B and Ramarao R., Identification and Validation of Potential Genotoxic Impurity in Rizatriptan by Ultra Performance Liquid Chromatography., Journal of Applied Pharmaceutical Science., 4th January 2024, Volume 14 (1), 212-220. doi: 10.7324/JAPS.2024.152121
25. Veeraswami B and Ramarao R., Identification and Validation of Genotoxic Impurity in Ezetimibe by Reverse Phase High-Performance Liquid Chromatography., Oriental Journal of Chemistry., 10th July 2023, Volume 39 (4), 896-903. DOI: http://dx.doi.org/10.13005/ojc/390410
26. Rama Rao R, et al. Development and Validation of Three Potential Genotoxic Impurities by Liquid Chromatography Single Quad Mass Detector in Iomeprol., Journal of Pharmaceutical Research International., 29th October 2021, Vol. 33 (Issue 47A), 756-767. doi: 10.9734/jpri/2021/v33i47A33071
27. Rama Rao R, et al. A Simple and Sensitive LC-MS/MS Method for Determination and Quantification of Potential Genotoxic Impurities in the Vismodegib Active Pharmaceutical Ingredient. Journal of Pharmaceutical Research International., 21st September 2021, Vol. 33 (Issue 44B), 88-102. doi: 10.9734/jpri/2021/v33i44B32654
28. Michael JB et al. Controlling a Cohort: Use of Mirabilis-Based Purge Calculations to Understand Nitrosamine-Related Risk and Control Strategy Options. Organic Process Research and Development. 2020, 24, 1531- 1535. doi: https://dx.doi.org/10.1021/acs.oprd.0c00264
29. Teasdale A et al. A Tool for the Semiquantitative Assessment of Potentially Genotoxic Impurity (PGI) Carryover into API Using Physicochemical Parameters and Process Conditions. Organic Process Research and Development. 2010, 14 (4), 943 - 945. doi: 10.1021/op100071n